A 15-person open-label pilot at Johns Hopkins reported 80 percent biologically confirmed seven-day point-prevalence abstinence at the six-month mark (Johnson et al., 2014). The 2017 long-term follow-up confirmed 67 percent at twelve months or longer (Johnson, Garcia-Romeu, and Griffiths, 2017). The comparison anchor matters more than the headline number. CDC 2024 data on standard cessation pharmacotherapy, including nicotine replacement, bupropion, and varenicline, places twelve-month biochemically confirmed abstinence under 35 percent in most cohorts.
The participants were not casual smokers. Average smoking history was 31 years. Average prior failed quit attempts was six. The cohort was self-selected, motivated, and screened, which limits generalization. The sample size limits it further. The Phase 2 randomized controlled trial NCT05452772 at Johns Hopkins is the confirmatory study currently enrolling. Until those readouts publish, the honest framing is that the pilot signal is large, durable, and preliminary.
The frame for the rest of this piece. What the data shows. What the protocol actually contained. Why a 5-HT2A agonist might address nicotine dependence at all. How the effect compares to standard pharmacotherapy. Where the study limitations sit. And why the founder cohort, who often carry decades-long smoking patterns alongside high-functioning depression and burnout, finds this literature unusually relevant. For deeper coverage of related mechanisms, see the MEQ30 as a predictor of clinical outcome and what an integration session actually looks like.
- The Johnson 2014 Johns Hopkins pilot reported 80 percent biologically confirmed seven-day point-prevalence abstinence at six months across 15 participants (PMID 25213996).
- The 2017 long-term follow-up confirmed 67 percent abstinence at twelve months or longer, with several participants sustaining abstinence at the 16-month average follow-up point (PMID 27441452).
- Standard cessation pharmacotherapy, including varenicline and nicotine replacement therapy, lands under 35 percent biochemically confirmed twelve-month abstinence per CDC 2024 and Cochrane review data.
- The participants averaged 31 years of smoking and six prior failed quit attempts. The cohort was the hardest-case end of the cessation population, not the easiest.
- The mystical-type experience intensity, measured by the MEQ30, statistically mediated the cessation outcome (PMID 29084459). The mechanism is not pharmacological substitution.
- The Phase 2 RCT NCT05452772 at Johns Hopkins is the confirmatory study currently enrolling. The pilot evidence is promising but not yet definitive.
What Does the Data Actually Say?
The headline numbers from the Johns Hopkins program are 80 percent at six months and 67 percent at twelve months or longer, both biologically confirmed. The 2014 pilot enrolled 15 nicotine-dependent adults across an open-label single-arm protocol combining cognitive behavioral therapy with two to three moderate to high dose psilocybin sessions (Johnson, Garcia-Romeu, Cosimano, and Griffiths, 2014). Biological confirmation used breath carbon monoxide and urine cotinine, not self-report.
The 2017 long-term follow-up tracked the same cohort at an average of 30 months post-quit-date. Twelve of the original 15 participants, exactly 67 percent, were classified as biologically confirmed abstinent at twelve months or longer (Johnson, Garcia-Romeu, and Griffiths, 2017). Nine participants were classified as continuously abstinent across the full follow-up window. The remaining three had relapsed and resumed smoking at varying levels.
The point-prevalence definition matters because cessation literature uses different abstinence definitions, and the comparison anchor needs to use the same one. Seven-day point-prevalence means no smoking in the seven days prior to the follow-up visit, biologically confirmed. Continuous abstinence is a stricter standard. The Johnson studies report both, and both substantially exceed standard pharmacotherapy benchmarks.
The Johnson, Garcia-Romeu, Cosimano, and Griffiths 2014 pilot enrolled 15 nicotine-dependent adults averaging 31 years of smoking history and six prior failed cessation attempts. The protocol combined 15 weeks of cognitive behavioral therapy with two to three moderate to high dose psilocybin sessions delivered in a monitored setting. At the six-month follow-up, 12 of 15 participants, exactly 80 percent, met seven-day point-prevalence abstinence criteria, biologically confirmed by breath carbon monoxide and urine cotinine. The 2017 long-term follow-up reported 67 percent abstinent at twelve months or longer. The effect size substantially exceeded historical rates for varenicline, nicotine replacement therapy, and bupropion across comparable cohorts. The signal is large but the sample is small, which is why the NCT05452772 Phase 2 randomized controlled trial is the next required step before clinical guidelines can shift.
Inside the Johns Hopkins Cessation Protocol
The cessation outcomes did not come from a single dose taken in isolation. The protocol ran for roughly 15 weeks and combined cognitive behavioral therapy, structured preparation, monitored dosing sessions, and integration. Pulling out the psilocybin and removing the rest does not produce the published outcomes. The protocol is the intervention.
Pre-Session Preparation and CBT
The first four weeks were structured CBT for smoking cessation combined with preparation sessions for the psilocybin component. Participants set a target quit date timed to the first dosing day. The CBT framework gave participants a behavioral vocabulary and a relapse-prevention toolkit that the psilocybin sessions later sat inside. Pulling the CBT out collapses the structure that integration depended on.
Two to Three Monitored Dosing Sessions
The first psilocybin session, on the target quit date, was a moderate dose of roughly 20 milligrams per 70 kilograms body weight. Subsequent sessions, two weeks and eight weeks later, used a higher dose near 30 milligrams per 70 kilograms unless the participant declined. Sessions took place in a furnished session room with two monitors, eyeshades, curated music, and the standard inward-attention orientation. The session itself lasted six to eight hours of acute effects.
Integration Across the Following Weeks
The weeks after each dosing session involved structured integration meetings. The participants reflected on the session content, mapped it onto the cessation work, and addressed cravings, slips, and identity shifts as they surfaced. The post-session plasticity window is the period during which the new behavioral pattern needed to consolidate, and the integration architecture was the consolidation infrastructure. For deeper coverage, see the psychedelic afterglow window.
Biological Confirmation, Not Self-Report
Abstinence at each follow-up was confirmed by breath carbon monoxide under 6 parts per million and urine cotinine under 200 nanograms per milliliter. This matters because self-reported abstinence in cessation research often overstates true abstinence by 10 to 20 percentage points. The Johnson numbers are biological, which removes the most common source of inflation in cessation literature.
Why Would a Psychedelic Help With Nicotine Addiction?
The mechanism is not pharmacological substitution. Psilocybin does not occupy nicotinic acetylcholine receptors or block dopamine reuptake the way bupropion does. The leading hypothesis is that the mystical-type experience, measured by the MEQ30 scale, mediates the cessation outcome. Garcia-Romeu and colleagues in 2014, and again with a larger pooled analysis in 2018, found that the intensity of the mystical experience during the high-dose session statistically predicted abstinence at follow-up (Garcia-Romeu et al., 2014, follow-up analysis 2018, PMID 29084459).
Identity Reframing in the Plasticity Window
The proposed psychological mechanism is meta-cognitive reframing. The smoker stops experiencing themselves as a person who needs to smoke. The identity that organized the behavior loosens, and the behavior loses its emotional anchor. This is different from suppressing craving with a partial agonist. The craving still arrives in the post-session weeks, but the meaning attached to it is different, and the behavioral response decouples.
The MEQ30 Mediation Finding
The MEQ30 is a 30-item scale that quantifies the intensity of the mystical-type experience along dimensions including unity, transcendence of time and space, ineffability, and noetic quality. Garcia-Romeu and colleagues found a statistically significant correlation between MEQ30 scores during the high-dose session and biologically confirmed abstinence at six months. The session intensity is not incidental. It appears to be the active ingredient. For deeper coverage, see the MEQ30 as a predictor of clinical outcome.
What This Is Not
This is not a story about psilocybin "rewiring" the brain in any neurologically specific sense that current imaging can confirm. The plasticity claim is real, but the specificity is not. The cessation outcome appears to depend on the subjective experience itself, the surrounding behavioral therapy, and the integration weeks, not on a molecular mechanism that targets nicotine dependence directly. This is closer to insight-based behavior change at high amplitude than to a substitution pharmacology.
Garcia-Romeu, Griffiths, and Johnson 2014, with extended pooled analysis in 2018, examined the relationship between mystical-experience intensity, measured by the 30-item MEQ30 scale, and cessation outcome in the Johns Hopkins psilocybin smoking cessation cohort. The MEQ30 captures subjective dimensions including unity, transcendence of time and space, ineffability, and noetic quality. Higher MEQ30 scores during the high-dose session statistically predicted seven-day point-prevalence abstinence at six months and beyond. The clinical implication is that the subjective experience itself appears to be the mediator of behavior change, not the molecular pharmacology in isolation. This mediation finding is consistent with parallel work in psilocybin treatment of major depressive disorder and end-of-life anxiety, where MEQ30 intensity has likewise predicted clinical outcome. The mechanistic model is meta-cognitive reframing in the post-session plasticity window rather than receptor-level substitution.
How Does This Compare to Standard Cessation Treatments?
The relevant comparison is biologically confirmed twelve-month abstinence under standard pharmacotherapy, which sits under 35 percent across most cohorts per CDC 2024 surveillance data and Cochrane meta-analyses. Varenicline, the most effective FDA-approved cessation medication, produces twelve-month continuous abstinence rates in the 20 to 33 percent range across pivotal trials. Nicotine replacement therapy and bupropion fall lower. The 67 percent at twelve months in the Johnson 2017 follow-up is roughly two to three times the comparison anchor.
Why the Difference Likely Exists
The mechanistic difference probably explains the gap. Varenicline targets nicotinic acetylcholine receptors as a partial agonist, suppressing craving and reducing reinforcement. The behavioral pattern, the identity layer, and the meaning attached to smoking are not addressed. When the participant stops the medication, the underlying psychology is unchanged, and relapse follows the predictable curve. The Johnson protocol appears to act on the identity layer directly through the session experience and the integration weeks, which is a different target.
Cohort Differences Cut Both Ways
The Johnson participants were self-selected, motivated, and screened against psychiatric contraindications. Standard cessation trial cohorts are broader and include participants with less motivation and more comorbidity. This favors the Johnson outcome at the margin. The Johnson cohort also averaged 31 years of smoking and six prior failed attempts, which is the hardest end of the cessation population. This cuts the other direction. Net, the cohort comparison is mixed but probably does not collapse the effect size.
The Pilot Carries Real Limitations
The Johnson 2014 pilot was open-label, single-arm, and enrolled 15 participants. The effect size is large enough to justify Phase 2 confirmation but small enough that prudence is the only defensible stance until the RCT publishes. The limitations are not hidden in the paper. The authors name them clearly. They matter for the decision-framing for any individual smoker considering this pathway.
Small Sample, No Control Arm
Fifteen participants cannot produce a definitive effect estimate. The 95 percent confidence interval around 80 percent six-month abstinence is wide, and the true population effect could land meaningfully lower. The absence of a control arm means the effect cannot be cleanly separated from the CBT component, the expectancy effect, or the intensive monitoring. The Phase 2 RCT addresses these by randomizing against an active comparator and powering to detect a smaller effect with confidence.
Self-Selected, Motivated Cohort
Participants who enroll in a psilocybin smoking cessation trial are an unusual subset. They are motivated enough to quit, open enough to consider a psychedelic, and willing to commit to the 15-week protocol. The outcome distribution in this cohort does not directly translate to the general smoking population. Real-world deployment, if and when it happens, will face a broader and less motivated set of participants.
Expectancy Effects Are Hard to Rule Out
Participants in an open-label trial of a novel psychedelic treatment carry strong expectancy. The expectancy itself can drive behavior change, especially in cessation where motivation is the dominant predictor. This does not invalidate the outcome but it does mean the effect attributable to the psilocybin specifically, separated from expectancy and the surrounding protocol, is not yet known. The RCT design controls for this through active comparator masking.
Phase 2 RCT NCT05452772
The confirmatory study is the Johns Hopkins Phase 2 randomized controlled trial NCT05452772, which is currently enrolling and uses a randomized active-comparator design. The readout from this trial is the next inflection point in the literature. Until it publishes, the honest framing for any individual considering this pathway is that the pilot signal is promising but the evidence base is not yet definitive.
"The pattern in the founder cohort that comes to me with long-tail smoking is rarely about nicotine. The cigarette is the spacer between identity and exhaustion. The Johnson protocol works on the spacer, not the molecule, which is why the integration weeks decide whether the change holds or unravels in the second month."
Why Does This Matter for Founders Specifically?
The founder cohort I work with carries an unusually high rate of long-tail smoking patterns alongside high-functioning depression, chronic burnout, and identity-fused work patterns. Across 900-plus integration sessions, the smokers in this population are often 15 to 30 years in, have tried multiple cessation pathways, and the smoking is rarely the surface problem. It is the spacer in an otherwise unsustainable load.
The Identity Fusion Pattern
Founders who smoke often built their work pattern around the cigarette as an integration unit. The cigarette marks the boundary between meetings, the pause before a hard conversation, the recovery after a launch. Removing the cigarette without addressing the integration function it served leaves a behavioral vacancy that nicotine replacement does not fill. The Johnson protocol seems to act on the identity fusion directly, which is structurally what this cohort needs.
The Burnout Overlap
The overlap between long-tail smoking and high-functioning depression in this cohort is substantial. The smoker often quit-and-relapsed in the periods of highest stress, which is exactly when the spacer function felt most necessary. Addressing the smoking in isolation rarely sticks. Addressing the burnout pattern and the smoking together has a different success curve. For deeper coverage of the underlying pattern, see psychedelics and high-functioning depression and psychedelics and decision-making.
What the Practical Path Looks Like Today
For the individual founder reading this in 2026, the practical path is narrow. The Phase 2 RCT NCT05452772 is the legal pathway and it is enrolling a small number of participants. Underground or retreat-context psilocybin use carries the contraindications and legal risks documented elsewhere on this site. The honest recommendation is to wait for the Phase 2 readout, evaluate at that point, and meanwhile use the standard pharmacotherapy pathways with realistic expectations about their effect ceiling.